BCL2 and B-cell chronic lymphocytic leukemia: In recent years, with the in-depth study of the pathogenesis of CLL and the clinical application of small molecule targeted drugs such as B-cell lymphoma-2 (BCL-2) inhibitors, the therapy of CLL has significantly improved (Woyach et al., 2014; Cervantes-Gomez et al., 2015).